Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
57 daily bars · split adjusted
Current price $13.83
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 31.28 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 22.45 | Oscillator | Neutral |
| Williams %R (14) | -83.64 | Oscillator | Buy |
| MACD (12, 26, 9) | -1.57 (Hist -0.03) | Oscillator | Strong Sell |
| Average Directional Index (14) | 29.16 (+DI 11.4 / -DI 24.6) | Trend | Strong Sell |
| EMA 20 | 15.84 | MA | Strong Sell |
| SMA 20 | 15.78 | MA | Strong Sell |
| EMA 50 | 18.65 | MA | Strong Sell |
| SMA 50 | 19.33 | MA | Strong Sell |
| SMA 200 | — | MA | Neutral |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | A-Award | 538,300 @ $17.00 | $9.15M |
| Aug 4, 26 |
| Chan Steven |
| officer: Chief Financial Officer |
| A-Award |
| 140,000 @ $17.00 |
| $2.38M |
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | 0 | — |
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | 0 | — |
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | 0 | — |
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | 0 | — |
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | 23,437 @ $1.58 | $37.01K |
| Aug 4, 26 | Fu Tao | director, officer: President and CEO | 409,709 @ $3.53 | $1.45M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ATTO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -14.9x | -18.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -3.4x | EPS est. -4.06 | Discount |
| Price / Book | 5.6x | 10.7x | Discount |
| Price / Sales | 1403.0x | 349.0x | Elevated |
| EV / EBITDA | -14.6x | -17.9x | Discount |
| Return on equity | -32.1% | — | Weak |
| Gross margin | -8.4% | 20.2% | Below hist. |
| Debt / Equity | 0.04 | 0.02 | Conservative |
| Piotroski / Altman Z | —/9 | Z — | n/a |
Discounted cash flow model
Stock news · updated daily
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.
Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.
Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.
Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) Director Colin Walsh purchased 85,000 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $21.00 per share, for a total transaction of $1,785,000.00. Following the acquisition, the director directly owned 85,000 shares in the company,
Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Global Strategic Fund Venbio purchased 382,352 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the completion of the acquisition, the
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 2, 2026 | -0.65 | -4.88 | Miss -655.5% | $450.0K |
| Jul 14, 2026 | — | -0.73 | — | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4/A | Oct 8, 2026 | 2026-10-08 20:00:58 | View |
| 4/A | Oct 8, 2026 | 2026-10-08 20:00:02 | View |
| 3/A | Oct 8, 2026 | 2026-10-08 19:58:36 | View |
| 3/A | Oct 8, 2026 | 2026-10-08 19:56:51 | View |
| 10-Q | Sep 2, 2026 | 2026-09-02 16:21:11 | View |
| 8-K | Sep 2, 2026 | 2026-09-02 16:17:18 | View |
| 144 | Aug 28, 2026 | 2026-08-28 17:50:44 | View |
| 4/A | Aug 28, 2026 | 2026-08-28 17:38:55 | View |
| 4/A | Aug 28, 2026 | 2026-08-28 17:38:09 | View |
| 4 | Aug 13, 2026 | 2026-08-13 21:52:51 | View |
Proxy statement (DEF 14A) disclosures